Meta-Analysis of Intraocular Bleeding with Dual Antiplatelet Therapy using P2Y12 Inhibitors Prasugrel or Ticagrelor

Intraocular bleeding is a devastating clinical event due to its potentially blinding nature. It is not known if determine if dual antiplatelet therapy using aspirin and potent P2Y12 inhibitors increases this risk. We searched MEDLINE and ClinicalTrials.gov for randomized controlled trials that were phase III, randomly assigned patients to dual antiplatelet therapy with either aspirin and a potent P2Y12 inhibitor or aspirin and clopidogrel, had follow-up of 6 months, and at least 200 patients. Corresponding authors were contacted for intraocular bleeding data.

Source: The American Journal of Cardiology - January 27, 2020 Category: Cardiology Authors: Michelle T. Sun, Sonia Huang, Stephen D. Wiviott, Elliot M. Antman, Matthew T. Roe, E. Magnus Ohman, Megan Neely, Lars Wallentin, Christopher X. Wong Source Type: research